Study on Cognitive Disorders of Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

November 30, 2011

Conditions
Multiple Sclerosis
Interventions
DRUG

Memantine

5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

DRUG

Placebo

5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

Trial Locations (1)

14033

CHU Caen, Caen

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

H. Lundbeck A/S

INDUSTRY

lead

University Hospital, Caen

OTHER

NCT01074619 - Study on Cognitive Disorders of Multiple Sclerosis | Biotech Hunter | Biotech Hunter